Newsroom
What's New With Genetesis.

Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux.

Congratulations to co-founder, Peeyush Shrivastava alongside co-founders Manny Setegn and Vineet Erasala and other winners for making the Forbes Under 30 list for healthcare - 30 of the brightest young entrepreneurs saving lives and creating a more equitable future.

Mithril Capital-led Series C to launch 5-minute noninvasive ischemia assessment requiring no pharmaceuticals, no exercise, and no radiation.

The group is comprised of world-class experts, researchers and thought leaders spanning cardiology, emergency medicine and radiology.

Ms.Medicine and Genetesis today announced the start of a clinical registry for Women’s Assessed Cardiovascular Evaluation with Magnetocardiography (WACE-MCG).

Genetesis, the company behind CardioFlux, explain how Magnetic Field Maps (MFMs) are created and interpreted.

Last month FDA designated Genetesis’ CardioFlux® as a Breakthrough Device for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.

CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms suggestive of acute coronary syndrome.

TDK Corporation (TSE: 6762) announces that subsidiary TDK Ventures Inc. adds to its growing portfolio of companies with an investment in Genetesis, a world leader in non-invasive biomagnetic imaging. (Photo: BusinessWire)

Genetesis has also added Sajid Malhotra to its Board of Directors. Malhotra brings extensive experience in senior executive positions in publicly traded companies.

COVID-19 is causing a large rise in non-cardiac elevations of biomarkers, sometimes just due to general multiorgan fulminant inflammation, severely complicating the traditional methods to diagnose myocardial infarction.

A 90-second chest scan could be a game-changer for triaging patients who present to the emergency department with undiagnosed chest pain, according to research out of Detroit.

View the process from start to finish of a patient being scanned with the CardioFlux MCG.

MedAxiom, the nation’s leading cardiovascular healthcare membership organization and performance community, is excited to announce its industry partnership with Genetesis, Inc.

A new pilot study has found that a resting 90-second magnetocardiography (MCG) scan shows promise in evaluating emergency department observation unit (EDOU) chest pain patients for Acute Coronary Artery Syndrome.

Work at WVU Medicine to use new technology to treat cardiac issues is gaining national attention and offering new options to patients.

CincyTech and the Ohio Innovation Fund led the round, which included significant investments from TDK Ventures and an undisclosed global health care company that ranks in the Fortune 500. (Image: Getty. Illustration: Chloe Krammel)

The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. 💵

Doctors at the WVU Heart and Vascular Institute are in clinical trials of a new technology that could make current methods of detecting heart disease obsolete. (Photo: TEDMED)

We asked you, the Cincinnati startup and entrepreneurial community, for input on which in-state companies were the ✨coolest✨— and you answered our call. Together, with editorial insight, we developed a list of entities whose culture stands out.

A Cincinnati medical device startup won a statewide award from VentureOhio, a group devoted to boosting the Buckeye State's entrepreneurial ecosystem, marking the second year in a row it has been honored by the organization.

Some of the most intriguing businesses the billionaire has backed didn't appear on 'Shark Tank.' (Photo: KCM/Getty)

Genetesis, a medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, has closed an oversubscribed round of $7.5M in Series A financing.